Efgartigimod for anti-NMDA receptor encephalitis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called efgartigimod, which may help people with anti-NMDA receptor encephalitis, a condition where the immune system attacks the brain. The study aims to see if it can improve symptoms when added to standard steroid treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 or older
- Diagnosed with anti-NMDA receptor encephalitis (a rare type of brain inflammation)
- Currently scoring 2 to 5 on the modified Rankin Scale (mRS), which measures how much help you need with daily activities
- If this is your first episode, you must not have received any prior immunosuppressive (immune-calming) therapy
- If you are having a relapse, you must have been on stable immunosuppressive treatment (like rituximab, mycophenolate, or corticosteroids) without improvement for at least 4 weeks
- Must have received at least 3 days of high-dose steroid infusions within the past 2 weeks and be willing to switch to oral steroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
This trial tests a medicine called efgartigimod to treat autoimmune encephalitis (AIE)—a rare condition where the immune system attacks the brain. The study enrolls children 12+ and adults to see if this drug can reduce symptoms and help recovery.
This trial tests a drug called efgartigimod for people having their first episode of optic neuritis (inflammation of the optic nerve). The goal is to see if it can help protect your vision better than standard treatment alone.
This study tests a new medicine (ART5803) in people whose immune system attacks a brain receptor called NMDAR, causing encephalitis (brain swelling) or psychiatric symptoms. It aims to see if the medicine can reduce symptoms like confusion, memory problems, or psychosis.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
Hear when a new Encephalitis Autoimmune trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.